Cytosorbents Corporation Share Price
Stocks
CTSO
US23283X3052
Advanced Medical Equipment & Technology
|
Market Closed -
Nasdaq
21:30:00 28/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 4.020 USD | -8.22% |
|
-30.09% | -68.55% |
| 08-06 | Cytosorbents Corporation, Q2 2026 Earnings Call, Aug 06, 2026 | |
| 08-06 | Cytosorbents Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| Market Cap | 13.8M 12.14M 11.48M 10.41M 19.57M 1.32B 19.67M 137M 53.02M 676M 51.81M 50.69M 2.17B | P/E 2026 * |
-0.91x | P/E 2027 * | -4.47x |
|---|---|---|---|---|---|
| Enterprise Value | 13.8M 12.14M 11.48M 10.41M 19.57M 1.32B 19.67M 137M 53.02M 676M 51.81M 50.69M 2.17B | EV / Sales 2026 * |
0.35x | EV / Sales 2027 * | 0.31x |
| Free-Float |
84.01% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CTSO | Delayed | |
CBOE
| CTSO | Real-time | |
|
Tradegate
| HQE | Real-time | |
|
Deutsche Boerse AG
| HQE | Delayed | |
|
Börse Stuttgart
| HQE | Delayed | |
|
Berne S.E.
| HQE1 | End-of-day quote |
Last Transcript: Cytosorbents Corporation
| 1 day | -8.22% | ||
| 1 week | -30.09% | ||
| Current month | -41.06% | ||
| 1 month | -40.95% | ||
| 3 months | -44.48% | ||
| 6 months | -66.10% | ||
| Current year | -68.55% |
| 1 week | 3.94 |  | 5.59 |
| 1 month | 3.94 | | 9.43 |
| Current year | 3.94 | | 16.89 |
| 1 year | 3.94 | | 20.4 |
| 3 years | 3.94 | | 43 |
| 5 years | 3.94 | | 164.6 |
| 10 years | 3.94 | | 299 |
| Manager | Title | Age | Since |
|---|---|---|---|
Phillip Chan
CEO | Chief Executive Officer | 55 | 23/07/2008 |
Peter Mariani
DFI | Director of Finance/CFO | 62 | 13/08/2024 |
Vincent Capponi
PSD | President | 68 | 27/04/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Edward Jones
BRD | Director/Board Member | 77 | 24/07/2011 |
Phillip Chan
BRD | Director/Board Member | 55 | 31/12/2008 |
Alan Sobel
BRD | Director/Board Member | 65 | 12/11/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 15/09/26 | Buy | Chief Executive Officer | 3,774 | 0.0060% | ||
| 15/09/26 | Buy | Director | 2,500 | 0.0040% | ||
| 14/09/26 | Buy | Chairperson | 2,073 | 0.0033% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.22% | -30.09% | -78.47% | -89.53% | 13.8M | |
| +0.53% | +4.17% | +46.17% | +36.19% | 250B | |
| +1.27% | +7.33% | +22.99% | -8.13% | 158B | |
| +2.37% | +5.46% | -5.97% | +42.33% | 143B | |
| +0.43% | +1.78% | -55.07% | -15.34% | 63.65B | |
| +0.63% | -1.62% | +13.88% | +23.85% | 49.74B | |
| +1.40% | +11.98% | +42.00% | +58.56% | 48.71B | |
| +2.33% | +2.38% | -14.54% | -18.18% | 47.94B | |
| +2.17% | +5.05% | +51.84% | +62.64% | 42.59B | |
| +0.70% | +13.47% | +196.54% | +103.98% | 40.77B | |
| Average | +0.07% | +1.39% | +21.94% | +19.64% | 84.4B | |
| Weighted average by Cap. | +0.54% | +4.03% | +27.31% | +27.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 38.88M 34.19M 32.34M 29.34M 55.12M 3.73B 55.41M 387M 149M 1.9B 146M 143M 6.12B | 44.16M 38.84M 36.73M 33.32M 62.6M 4.24B 62.94M 440M 170M 2.16B 166M 162M 6.95B |
| Net income | -13.91M -12.23M -11.57M -10.5M -19.72M -1.34B -19.82M -138M -53.44M -681M -52.22M -51.09M -2.19B | -2.77M -2.44M -2.31M -2.09M -3.93M -266M -3.95M -27.6M -10.65M -136M -10.4M -10.18M -436M |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/09/26 | US$4.020 | -8.22% | 14,254 |
| 25/09/26 | US$4.380 | +1.86% | 6,532 |
| 24/09/26 | US$4.300 | -12.42% | 24,869 |
| 23/09/26 | US$4.910 | -7.71% | 6,107 |
| 22/09/26 | US$5.320 | -3.45% | 6,350 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CTSO Stock
Select your edition
All financial news and data tailored to specific country editions
